Mellon backs early-stage genetics fund
IRegent, Jim Mellon’s Hong Kong investment group, provides initial backing for a new genetic medicine fund.
29 December 2012•1 min read
IRegent, Jim Mellon’s Hong Kong investment group, provides initial backing for a new genetic medicine fund.
Side Letter: First through the breach
22 October 2026 · 3 mins read
Blackstone’s private wealth AUM hits $330bn as BXPE posts best quarter
22 October 2026 · 3 mins read
Succession: Why waiting too long can price out the next generation
22 October 2026 · 5 mins read
Side Letter: 15,000's a crowd
22 October 2026 · 3 mins read
HK's Sun Hung Kai & Co ramps up PE pacing as liquidity improves
22 October 2026 · 5 mins read
Hamilton Lane's Hirsch: Private markets industry has too many GPs
22 October 2026 · 1 min read
Defence funds flood Europe, though mid-market remains ‘largely untouched’
21 October 2026 · 4 mins read
